GRCL — Gracell Biotechnologies Balance Sheet

0.000.00%

Last trade - 00:00

HealthcareSpeculativeMid CapNeutral

Annual balance sheet for Gracell Biotechnologies, fiscal year end - December 31st, CNY millions except per share, conversion factor applied.

	2018 December 31st	2019 December 31st	2020 December 31st	2021 December 31st	2022 December 31st
Period Length:	—	—	—	—	—
Source:	PROSPECTUS	PROSPECTUS	20-F	20-F	20-F
Standards:	USG	USG	USG	USG	USG
Status:	Final	Final	Final	Final	Final
Cash and Equivalents
Short Term Investments
Cash and Short Term Investments	117	320	776	1,837	1,462
Net Total Receivables	6.2	13.8	31	40.7	26.3
Prepaid Expenses
Total Other Current Assets
Total Current Assets	128	340	815	1,885	1,496
Gross Property, Plant And Equipment
Accumulated Depreciation
Net Property, Plant And Equipment	16.3	48.3	119	153	145
Other Long Term Assets
Total Assets	149	412	965	2,060	1,656
Accrued Expenses
Notes Payable / Short Term Debt
Current Portion of Long Term Debt / Capital Leases
Total Other Current Liabilities
Total Current Liabilities	7.44	18.2	93.4	155	221
Long Term Debt
Total Long Term Debt
Total Debt
Total Other Liabilities
Total Liabilities	146	157	145	233	281
Redeemable Preferred Stock
Common Stock
Additional Paid In Capital
Retained Earnings (Accumulated Deficit)
Other Equity
Total Equity	2.38	255	820	1,827	1,376
Total Liabilities & Shareholders' Equity	149	412	965	2,060	1,656
Total Common Shares Outstanding
Total Preferred Shares Outstanding